Accord BioPharma received approval for Filkri, a filgrastim biosimilar, and Outlook Therapeutics journey to approval for its ONS-5010 continues after an FDA rejection. A Filkri Approval for Accord BioPharma In mid-February, Accord BioPharma announced that it had received FDA approval for Filkri (filgrastim-laha), making it the fifth filgrastim biosimilar to obtain approval (not counting Granix, … Continue reading A Filgrastim Biosimilar Approval, and a Bevacizumab Rejection